332 related articles for article (PubMed ID: 31448830)
1. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.
El Haddad L; Ghantoji SS; Park AK; Batista MV; Schelfhout J; Hachem J; Lobo Y; Jiang Y; Rondon G; Champlin R; Chemaly RF
J Med Virol; 2020 Jan; 92(1):86-95. PubMed ID: 31448830
[TBL] [Abstract][Full Text] [Related]
2. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation.
Peffault De Latour R; Chevallier P; Blaise D; Alami S; Lévy-Bachelot L; Allavoine T; Tadmouri A; Blomkvist J; Duhamel A; Srour M; Beauvais D; Yakoub-Agha I
J Med Virol; 2020 Dec; 92(12):3665-3673. PubMed ID: 32297984
[TBL] [Abstract][Full Text] [Related]
4. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan - a retrospective database study.
Ueno R; Nishimura S; Fujimoto G; Piao Y; Takenaka K
Curr Med Res Opin; 2019 Dec; 35(12):2089-2096. PubMed ID: 31353971
[No Abstract] [Full Text] [Related]
5. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
7. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
[TBL] [Abstract][Full Text] [Related]
8. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.
Zavras P; Su Y; Fang J; Stern A; Gupta N; Tang Y; Raval A; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1482-1491. PubMed ID: 32315708
[TBL] [Abstract][Full Text] [Related]
9. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.
Fang J; Su Y; Zavras PD; Raval AD; Tang Y; Perales MA; Giralt S; Stern A; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1937-1947. PubMed ID: 32640313
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.
Chen J; Abella Ross J; Tegtmeier B; Yang D; Ito JI; Zaia JA; Dickter JK; Nakamura R; Mokhtari S; Kriengkauykiat J; Al Malki MM; Dadwal SS
Transpl Infect Dis; 2020 Apr; 22(2):e13233. PubMed ID: 31840347
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review.
Cho SY; Ar MC; Machado CM; Wu D; Singh I; Sandhu A; Demuth D; Slavin M
Transpl Infect Dis; 2023 Aug; 25(4):e14083. PubMed ID: 37287436
[TBL] [Abstract][Full Text] [Related]
13. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
14. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
[TBL] [Abstract][Full Text] [Related]
15. Comparison of valganciclovir
Zhu J; Xu M; Ru Y; Gong H; Ding Y; Zhu Z; Xu Y; Fan Y; Zhang X; Tu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Song T; Wu D; Chen J
Leuk Lymphoma; 2024 Jun; 65(6):816-824. PubMed ID: 38475670
[TBL] [Abstract][Full Text] [Related]
16. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
Talaya A; Giménez E; Piñana JL; Albert E; Hernández-Boluda JC; Pérez A; Torres I; Solano C; Navarro D
J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
[TBL] [Abstract][Full Text] [Related]
17. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
Chan ST; Logan AC
Blood Rev; 2017 May; 31(3):173-183. PubMed ID: 28173959
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
19. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
